State menopause mandates are creating a new insurance coverage category in real time

Why this matters

In July 2002, the Women’s Health Initiative (WHI) halted its estrogen-plus-progestin trial and issued a press conference that triggered a global panic about hormone replacement therapy (HRT). Within nine months, HRT prescriptions dropped 32%. Doctors stopped prescribing. Medical schools stopped teaching menopause care. An entire generation of women entered menopause with no clinical support.

Twenty-four years later, that overcorrection is finally being undone. Not by medicine, but by state legislatures.

The data

Where mandates stand

Seven states have acted. Seven more are moving. The rest haven’t started.

Louisiana was the first mover. Its HB 392, effective August 2024, covers both Medicaid and private insurance and bans prior authorization for HRT. New Jersey’s A5278, signed January 2026, is the most comprehensive so far: it mandates coverage for hormone therapy, non-hormonal treatments, pelvic floor physical therapy, bone health screening, behavioral health care, and patient counseling. Rhode Island took a different path. Its HB 6161 is the first workplace accommodation mandate, requiring employers with four or more employees to provide reasonable accommodations for menopause symptoms.

Among the pending states, Ohio’s HOTTIE Act (Hormone Optimization Treatment Through Insurance Expansion, HB 767) stands out. Introduced in March 2026 with 19 co-sponsors, it explicitly cites the FDA’s February 2026 removal of HRT black box warnings as justification. New York’s A5444 would eliminate deductibles, copays, and coinsurance entirely for menopause treatment.

California is the cautionary tale. Governor Newsom vetoed menopause insurance bills twice, first AB 2467 in September 2024 and then AB 432 in October 2025, despite near-unanimous legislative support (Assembly 70-1, Senate 39-0). He called the coverage “too far-reaching.” His compromise: a 2026 budget trailer bill with narrower scope.

The treatment gap

The gap between how many women need menopause care and how many get it is staggering. Only 26% of women have full insurance coverage for menopause prescriptions. Among those who seek clinical help, 75% go untreated. More than 80% never seek care at all.

The economic cost runs to $26.6 billion annually in the US alone, with $1.8 billion in lost work time and the rest in medical expenses. A 2025 Stanford/University College London (UCL) study found that women who seek menopause medical care experience a 10% earnings cut within four years. The impact is concentrated among women without college degrees.

The punchline: fixing this costs almost nothing. California’s independent actuarial review by the California Health Benefits Review Program (CHBRP) found that menopause insurance mandates add approximately 0.05% to premiums. That’s the gap between a $26.6 billion problem and a rounding error on insurance costs.

Racial disparities in access

The treatment gap hits hardest along racial lines.

Black women are 26% less likely to be prescribed HRT than white women, despite experiencing menopause symptoms for significantly longer: an average of 10 years compared to 6.5 years for white women. Hispanic women are 32% less likely to receive HRT and experience symptoms for 8.9 years on average.

The SWAN (Study of Women’s Health Across the Nation) study documented that Black women also reach menopause 8.5 months earlier than white women. When weathering effects (cumulative stress from discrimination) are accounted for, Black and Hispanic women enter menopause 1.2 years earlier.

The mandate wave has the potential to narrow these gaps, but only if the mandates are accompanied by provider training. Currently, only 20% of obstetrics and gynecology (OB/GYN) residency programs include menopause education. New Jersey and Maine have begun addressing this with education requirements, but most enacted mandates focus on insurance coverage alone.

How the movement built

The movement’s inflection point was 2024. Dr. Mary Claire Haver’s The New Menopause became a #1 NYT bestseller. Halle Berry shouted “I’m in menopause!” outside the Capitol. Louisiana passed the first comprehensive mandate. The Biden executive order on women’s health research added federal legitimacy. Then, in February 2026, the FDA removed HRT black box warnings, reversing the very decision that triggered the 2002 crisis and giving state legislatures the clinical cover they needed.

What to watch next

• California’s budget approach: if Newsom’s trailer bill passes, it proves the “narrow mandate via budget” path works for resistant governors
• Ohio’s HOTTIE Act: the first bill to explicitly cite the 2026 FDA warning removal as justification, and a potential template for other states
• Federal action: the Advancing Menopause Care and Mid-Life Women’s Health Act ($275M) has 17 Senate co-sponsors but hasn’t advanced. The Employee Retirement Income Security Act (ERISA) preemption gap means state mandates can’t reach self-insured plans. Only federal action can close it.
• Employer response: whether self-insured employers voluntarily adopt menopause benefits to compete for talent, regardless of state mandates
• Provider training: whether states pair insurance mandates with education requirements. Coverage without competence just shifts the bottleneck.